INTRODUCTION
Asthma is a multifactorial chronic inflammatory disease of the lung that is characterized by airway hyper-responsiveness (AHR 1 ). Disease progression involves broncho-constriction, recruitment of leukocytes, airway remodeling and increased smooth muscle mass (10) . Many factors are proposed to contribute to the initiation and progression of asthma including genetic predisposition and environmental factors such as pollutants (9) . The increased co-incidence of obesity and asthma, as observed with recent longitudinal and cross-sectional studies (16, 42) , further suggests that metabolic dysregulation may also contribute to AHR. As well, hypercholesterolemia, which is often observed in obese patients with asthma, has been associated with AHR in animal models of lung disease (1, 33, 47) . Consistent with the latter, statin therapy has been shown to reduce pulmonary inflammation and proliferation of airway smooth muscle cells (39, 47) . Further evidence to support a crucial role for lipid homeostasis in the lung come from animal studies of the ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. ABCA1 and ABCG1 mediate cholesterol and phospholipid efflux from peripheral cells to extracellular acceptors such as apolipoprotein AI (apoAI) and high density lipoprotein (HDL) for transport back to the liver in a process termed 'reverse cholesterol transport' (45) . Severe pulmonary abnormalities are observed in both ABCA1 and ABCG1 knockout mouse models. Thus, abca1
-/-mice display massive lipid accumulation in alveolar macrophages, type II pneumocytes and lung parenchyma, abnormal lung morphology and shallow breathing (6) . Similarly, abcg1 -/-mice display progressive lipid accumulation in alveolar macrophages and type II pneumocytes (5).
Moreover, patients who suffer from pulmonary alveolar proteinosis (PAP) have reduced ABCG1 expression in alveolar macrophages (40) . Interestingly, gm-csf -/-mice, which recapitulate disease phenotypes of PAP patients, show reduced ABCG1 expression in alveolar macrophages, implicating ABCG1, as well as the pro-inflammatory cytokine GM-CSF, as crucial regulatory components of lipid and surfactant metabolism in the lung (40) . Taken together, the foregoing indicates that metabolic defects in lipid and cholesterol homeostasis may contribute to AHR and lung disease; however, the physiological relevance and mechanisms involved remain unknown.
While ABC transport proteins have been highly characterized in the macrophage, their role in other lung cell types, such as human airway smooth muscle (hASM) , that are crucial in diseases such as asthma, has not been investigated. hASM cells regulate bronchomotor tone, contribute to exaggerated broncho-constriction (hyper-responsiveness) during an asthmatic attack and to increased smooth muscle mass in the asthmatic airway which leads to airway constriction and eventual irreversible tissue remodeling (2) . ASM cells also mediate immune modulation and inflammation in the airway by promoting the recruitment, activation, and migration of inflammatory cells through the expression of cytokines and inflammatory mediators (21) . We have recently demonstrated that both ABCA1 and ABCG1 are highly expressed in hASM and that their expression is regulated by liver X receptor (LXR; subtypes α and β), a ligand-activated nuclear hormone receptor that governs cholesterol and fatty acid homeostasis by controlling the expression of key target genes that control cholesterol catabolism, storage, adsorption, and transport (13) .
Ligand-activation of LXR also results in robust cholesterol efflux in ASM cells, presumably through the actions of ABC transporters. Given the emerging importance of cholesterol and lipid metabolism in the lung, we sought to further characterize the function of ABCA1 and ABCG1 in hASM cells using siRNA knockdown approaches and small molecule inhibitors of these transporters. We show here that LXR-ligand induced reverse cholesterol and phospholipid transport to both apoAI and HDL is mediated exclusively by ABCA1 whereas ABCG1 appears to play no observable role in this process. Moreover, we show that cholesterol-loading of hASM cells specifically increases the expression of ABCA1 and ABCG1, and that this induction is dependent on LXRα/β expression. Our findings indicate that cholesterol and lipid homeostasis are of importance in normal hASM function and suggest that dysregulation of these pathways may contribute to the pathogenesis of respiratory diseases such as asthma.
MATERIALS AND METHODS
Reagents: Human apolipoprotein A-I (apoAI), TO901317 (T1317), GW3965, 9-cis retinoic acid (9-cisRA), Interleukin 1-β (Il-1β) and probucol were purchased from Sigma-Aldrich (Oakville, ON, CA). Human high density lipoprotein (HDL) purified by ultracentrifugation (d=1.063-1.21g/cc) was purchased from Biomedical Technologies (Stoughton, MA, USA). 3 H-cholesterol and 3 H-choline were purchased from Perkin Elmer (Boston, MA, USA). Gene-specific siRNA oligonucleotides were purchased from QIAGEN (Chatsworth, CA, USA). All other chemicals were purchased from Sigma-Aldrich unless stated otherwise.
Human airway smooth muscle (hASM): hASM cells were obtained as described previously (29) from human lungs that were resected at St. Joseph's Healthcare (Hamilton, Canada), following approval from the Institutional Review Board and the consent of patients undergoing resection. Cholesterol Efflux: Cholesterol efflux assays were carried out as previously described (13) with minor modifications. Briefly, hASM cells were split into 48-well dishes at a concentration of 5x10 5 cells/well and allowed to adhere overnight followed by incubation for 48hrs in DMEM + 10%FBS + 3 H-cholesterol (5μCi/ml). Cells were then washed and incubated for an additional 18hrs with equilibration medium (DMEM + 2% BSA) supplemented with T1317 (1μM), 9-cisRA (1μM) and probucol (10μM) where indicated. Efflux was initiated by the addition of efflux medium (DMEM + 0.2% BSA) plus either, vehicle, apoAI (50μg/ml) or HDL (50μg/ml) where indicated.
Radioactivity was measured by scintillation counting and cholesterol efflux was calculated by dividing the amount of 3 H-cholesterol in the media by the total 3 H-cholesterol associated with the cells plus media. For efflux experiments using cells that were transfected with siRNA, cell plating and transfections were done on the same day and the siRNA complex was incubated with the cells overnight. The following day, the media was removed, and replaced with labeling media and incubated for 48hrs as described above.
Western Blot Analysis: hASM cells were transfected with siRNA (50nM) as indicated in the figure legends, and cholesterol efflux assays were carried out as described above. Total protein was then isolated using 1% triton X-100 detergent and Western blot analysis was carried out (25μg total protein for each sample) using a commercially available kit Phospholipid Efflux: Phospholipid efflux assays were carried out as previously described (43) .
Briefly, hASM cells were split into 48-well dishes at a concentration of 5x10 5 cells/well and allowed to adhere overnight. The media was then replaced by DMEM + 2% BSA + 3 H-choline (5μCi/ml) and cells incubated for 48hrs. Cells were washed and incubated for an additional 18hrs
in DMEM + 2% BSA supplemented with T1317 (1μM) and 9-cisRA (1μM) where indicated.
Phospholipid efflux was initiated by the addition of efflux medium (DMEM + 0.2% BSA) plus either, vehicle, apoAI (50μg/ml) or HDL (50μg/ml) where indicated in a total volume of 250µl.
Supernatants (200µl) were collected after 5hrs and lipid was extracted using Folch mixture (chloroform:methanol (2:1)) and measured by scintillation counting. Lipids were extracted from cell monolayers using the hexane:isopropanol method as described (43) . Phospholipid efflux was calculated as the amount of extracellular 3 H-choline / total 3 H-choline associated with the lipid fraction of the cells plus media.
Cholesterol loading and unloading with methyl-β-cyclodextrin: hASM cells were plated in 6-well dishes and allowed to adhere overnight, transfected with the indicated siRNA as described above and serum starved for 24hrs in 0.2% BSA-RPMI. Cells were then incubated with methyl-β-cyclodextrin (MβCD, 5µg/ml) or methyl-β-cyclodextrin in complex with cholesterol (5µg/ml) (Sigma) in 0.2% BSA-RPMI for an additional 24hrs where indicated in the figure legends. RNA was isolated and quantified by RT-PCR as described above.
Analysis of HDL and ApoAI preparations by FPLC:
Purified HDL and pure apoAI described above were separated by gel filtration chromatography using an AKTA FPLC with a Superose 6 HR 10/30 column and eluted into eighty 250µl fractions (35). Fractions were analyzed for total cholesterol using the Infinity Cholesterol Liquid Stable Reagen Kit according to manufacturer's instructions (Thermo Electron, Pittsburgh, PA, USA). HDL and free apoAI fractions were also analyzed for apoAI content by western blot as described above. Briefly, 10µls of each fraction was separated by SDS-PAGE and transferred to nitrocellulose. Blots were incubated with goat antiapoAI (1:10000) (Midland Bioproducts, Boone, IA, USA) for 1hr followed by rabbit anti-goat horseradish peroxidase-conjugated secondary antibody (1:10000) (Amersham) for an additional hour and visualized by enhanced chemiluminescence.
Statistical Analysis: Unpaired t tests were used for comparison of groups. P < 0.05 was considered significant.
RESULTS

ABCA1, but not ABCG1, mediates LXR-stimulated cholesterol efflux to apoAI and HDL -We have previously demonstrated that activation of endogenous LXR in hASM cells by various receptor
agonists induces expression ABCA1 and ABCG1 at the mRNA and protein levels, and stimulates cholesterol efflux (13) . To determine if reverse cholesterol transport in hASM cells requires ABCA1 and/or ABCG1, and, if so, to assess the contribution of each receptor in this process, we employed knockdown strategies using small interfering RNAs (siRNAs) to specifically reduce the expression of ABCA1 or ABCG1 and tested the effects on cholesterol efflux. As previously demonstrated, cholesterol efflux in ASM cells, using apoAI as an acceptor, was increased 2-fold over control levels in the presence of the LXR ligand T1317 and 9-cisRA, a ligand for the LXR obligate heterodimerization partner retinoic-X-receptor (RXR) (Fig. 1A) . Knockdown of ABCA1, but not ABCG1, blocked all LXR-ligand induced cholesterol efflux to apoAI acceptor. To determine the efficiency and specificity of knockdown of ABC transporters, we isolated RNA and protein from cells treated in parallel during the cholesterol efflux assays and analyzed expression levels by RT-PCR and western blot analysis. As shown in Fig.1 , siRNAs targeted to ABCA1 or ABCG1 showed specific and efficient knockdown of each respective transporter at both the RNA (Fig. 1B ) and protein levels (Fig. 1C) . In each case, LXR-dependent induction over control levels was reduced 85-95%. These above findings establish that ABCA1 is necessary and sufficient for LXR-mediated cholesterol efflux to apoAI.
Previous reports have suggested that in macrophages, ABCG1 is responsible for preferential cholesterol efflux to the lipid-rich acceptor HDL. To determine if this is also the case in hASM cells, we repeated the above experiment with HDL in place of apoAI. As shown in Fig.   2A , LXR activation increased cholesterol efflux to HDL by 2-fold over control levels.
Surprisingly, knockdown of ABCG1 did not alter the ability of hASM cells to efflux cholesterol to HDL ( Fig. 2A) . Thus, in contrast to what has been reported in the macrophages (18, 27, 41, 44) , HDL does not serve as a cholesterol acceptor for ABCG1-mediated cholesterol efflux in hASM cells. In order to identify which transporters were responsible for cholesterol efflux to HDL, we investigated the role of the scavenger receptor B1 (SR-BI) and ABCA1, both of which have also been reported to efflux cholesterol to HDL in macrophages (13, 14, 28) . Knockdown of SR-BI (>80%) had no effect on efflux to HDL acceptors ( Fig. 2B and C) whereas knockdown of ABCA1 blocked all LXR ligand-induced efflux to HDL (Fig. 2A) . To ensure that the observed efflux was not due to contaminating free apoAI in the HDL preparations, we fractionated HDL and pure apoAI protein preparations by FPLC. ApoAI in the HDL preparations eluted in fractions rich in cholesterol and as a distinct and separate peak, with only minor overlap, compared to pure apoAI (not shown). These findings indicate that the majority of the apoAI in the HDL preparations was associated with HDL particles and not in free form. Furthermore, the observation that the raw percentage of cholesterol efflux observed with HDL preparations was greater compared to free apoAI (compare Fig.1A vs Fig. 2A ) despite using equivalent protein amounts (50µg/ml), indicates that ABCA1-dependent cholesterol efflux to HDL was not a result of contaminating free apoAI in the HDL preparations. The finding that ABCA1 mediated efflux to HDL was further confirmed by using an independent siRNA construct to reduce expression of ABCA1 (Fig. 2D ) and by undertaking dose-response and time-course experiments. As shown in Fig. 3 , increasing amounts of ABCA1 siRNA blocked LXR-stimulated efflux in a dose-dependent manner, an effect that was evident within 1-2 hours (Fig. 4A and 4B ). To independently confirm that ABCA1 is involved in cholesterol efflux to both HDL and apoAI, cells were incubated with probucol, a small molecule that has been shown to specifically block ABCA1-dependent cholesterol efflux, while having no effect on ABCG1 (15) . As shown in Fig. 5A , probucol, inhibited all LXR-mediated cholesterol efflux to both HDL and apoAI while having no affect on cell viability (Fig. 5B) . The foregoing establishes that ABCA1 mediates all LXR ligand-induced cholesterol efflux in hASM cells to both apoAI and HDL acceptors and moreover, that ABCG1 is not involved in this process. Table I , ABCA1 and ABCG1 expression levels were induced 11-fold and 18-fold, respectively, by cholesterol loading, while expression levels were decreased by 70-90% by cholesterol depletion, relative to controls. As expected, knockdown of LXRα/β isoforms blocked the induction of ABCA1 and ABCG1 following cholesterol loading (Table 1) . Thus, both ABCA1 and ABCG1 mRNA levels are sensitive to cellular cholesterol levels. These findings imply that ABCG1 does in fact respond to changes in cholesterol levels in hASM cells; however, its precise physiological role remains to be determined. (32, 36) . It is interesting to note that asthma is in many ways a disease analogous to atherosclerosis in that both diseases are characterized by chronic inflammation and involve increased smooth muscle hyperplasia and hypertrophy, pro-inflammatory gene expression, lesion development, extracellular matrix remodeling, and infiltration of inflammatory leukocytes. Analogous to atherosclerotic lesions, the airways of asthmatic patients display endothelial and microvascular damage which is thought to expose the lung to blood plasma and its constituents including lipoprotein particles such as LDL (34) . Thus, the asthmatic airway may be subject to a similar inflammatory microenvironment as vascular cells following endothelial damage.
Phospholipid efflux in hASM is mediated by ABCA1 -
DISCUSSION
Using siRNA knockdown approaches, we have shown that ABCA1 is necessary and sufficient for all LXR-ligand induced cholesterol and phospholipid efflux in hASM cells whereas ABCG1 appears not to be required. We further demonstrate that ABCA1 effluxes cholesterol to both apoAI and HDL acceptors, in concordance with others who have shown, in endothelial cells, that ABCA1 but not ABCG1 mediates cholesterol efflux to HDL (22, 26) . We confirmed these results using probucol, a small molecule inhibitor specific for ABCA1 as demonstrated by the ability of this compound to inhibit cholesterol efflux in normal fibroblasts but not in fibroblasts derived from Tangier's patients which lack ABCA1 (15) . The raw percentages of efflux observed from hASM to both apoAI (4-14%) and HDL (30-40%) are also highly consistent with previous reports in other cell types including macrophages (15, 22) . Recently, Mukhamedova et al. (25) using in vitro labeled cells injected into mouse models have shown a correlation between in vitro cholesterol efflux percentages and in vivo reverse cholesterol transport providing evidence that hASM cells potentially function in vivo to regulate reverse cholesterol transport.
Recently, cholesterol mass efflux to HDL was reported to be dramatically reduced in peritoneal macrophages isolated from abca1 -/-mice however, abcg1 -/-mice also displayed reduced capacity to efflux cholesterol to HDL, suggesting that in macrophages, both transporters contribute to efflux to HDL (28). These findings point to a possible cell-type specific role for ABCG1 and cholesterol efflux in macrophages compared to smooth muscle cells. Why airway smooth muscle cells differ from the macrophage in mechanisms of cholesterol efflux to HDL is currently unclear.
The macrophage is a highly specialized cell able to phagocytose extracellular materials including apoptotic cells and surfactant (12) . Both processes dramatically increase intracellular sterol content and thus, alveolar macrophages have possibly evolved separate mechanisms to handle increased intracellular lipids (12) . Additionally, it is possible that macrophage cell types may express additional co-factor proteins that work in conjunction with ABCG1 to mediate efflux of lipids that are not present in hASM. Thus, for hASM cells, it is perhaps sufficient and efficient that ABCA1
can both lipidate apoAI particles to form nascent HDL and in addition, further lipidate HDL itself.
While ABCG1 is robustly induced in hASM cells by activation of LXR, its function in these cells remains unclear. Recent findings indicate that ABCG1 -/-mice have elevated levels of multiple pro-inflammatory mediators in the lungs (4) and it was suggested that this was likely due to local elevated cholesterol levels. However, the progressive lipid accumulation observed in abcg1 -/-mice can be reversed by bone-marrow transplantation of wild-type cells suggesting that hematopoietic ABCG1 is required for proper lipid homeostasis in the lung (46) . In agreement with these findings, we did not observe an effect on LXR-induced cholesterol transport after ABCG1 knockdown in ASM, a non-hematopoietic cell. Whether ABCG1 is linked to roles unrelated to direct lipid efflux in hASM cells (eg. intracellular lipid trafficking) remains to be tested. Recently, transforming growth factor β (TGFβ) signaling has been shown to specifically increase the expression of ABCG1 and not ABCA1 (3). Since TGFβ plays a fundamental role in ECM production in hASM cells, it is possible that ABCG1 has a function in this context (24, 30) .
Our findings raise several questions as to the role of cholesterol efflux and metabolism to AHR in vivo. While we, and others, have shown that LXR agonists reduce the inflammatory response in multiple lung cell types (13, 38) , a direct correlation between reverse cholesterol transport and AHR remains to be determined in vivo. Baldan et al. have proposed that cholesterol itself is pro-inflammatory (4) and thus, elevated levels may exacerbate an inflammatory milieu thereby accelerating the remodeling process occurring in the asthmatic lung. LXR's beneficial effects may thus be partially due to efflux of excess cholesterol for transport back to the liver and eventually excretion via an ABCA1-dependent mechanism. In support of this, statin therapy, a cholesterol lowering drug, is recently reported as a potential therapeutic avenue for the treatment of lung diseases (11, 19, 31 ).
In summary, we demonstrate that LXR-ligand induced cholesterol and phospholipid efflux in airway smooth muscle cells is mediated exclusively by ABCA1 and that elevated levels of cholesterol affect biological processes that are highly relevant to the pathophysiology of asthma.
Our findings may thus have relevance to understanding the molecular mechanisms that link obesity and hypercholesterolemia to airway diseases such as asthma. Future studies investigating the mechanisms of high cholesterol diet on AHR and the effects of LXR-activation in vivo will provide evidence to support cholesterol lowering as a potential therapeutic avenue in treating asthma in hypercholesterolemic and obese patients. Table 1 -ABCA1 and ABCG1 mRNA levels are increased by cholesterol loading and decreased by cholesterol depletion. hASM cells were transfected with the indicated siRNA and serum-starved for 24hrs followed by treatment with vehicle (0.2% BSA), methyl-β-cyclodextrin (MβCD) (5μg/ml) alone or MβCD in complex with cholesterol (MβCD:Chol) (5μg/ml) for an additional 24hrs. RNA was then isolated and levels of ABCA1 and ABCG1 were quantified by real-time PCR. The data represents relative fold changes and are the average of triplicates (+/-S.D.) normalized using β-actin as an internal standard with control vehicle treated taken as 1. *p<0.05 vs control indicated by †
